Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06449313 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement | PHASE2 | RECRUITING | 21 | — | — | Apr 1, 2026 | Sep 1, 2032 | Feb 12, 2026 | 3 | United States |
Pathologic complete response (pCR): 0% viable tumor in primary tumor and resected lymph nodes.
| Arm | Type | Description |
|---|---|---|
| Cemiplimab plus chemotherapy | EXPERIMENTAL | cemiplimab given with standard of care chemotherapy for 4 treatments/cycles before surgery and then every 3 weeks for 1 year after surgery. |
| Name | Type | Description |
|---|---|---|
| Cemiplimab-Rwlc | DRUG | 350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year. |
Inclusion Criteria: 1. Age ≥ 18 years at time of signing the informed consent form (ICF). 2. Histologically or cytologically confirmed stage 3 B/C Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJCC) with pathologically-confirmed contralateral mediast...